{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:16:32Z","timestamp":1789049792499,"version":"build-2803163510"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Most cancer therapies target genetic alterations driving tumor growth, but many drivers are undruggable or rare, limiting their therapeutic reach. Here, we demonstrate that amplified genes encoding cell surface proteins provide a rich, cancer-driver\u2013agnostic source of targets. We identify MPZL1 (myelin protein zero\u2013like 1), amplified in up to 75% of patients with certain solid tumor types, as abundantly expressed on the surface tumor cells across diverse cancer types while being largely absent from healthy tissues, offering a favorable therapeutic window. We develop a monoclonal antibody targeting MPZL1\u2019s extracellular domain and engineer chimeric antigen receptor (CAR)-T cells that selectively eliminate MPZL1-positive cancer cells in vitro. These CAR-T cells exhibit antitumor activity in human xenograft, autochthonous mouse, and patient-derived tissue explant preclinical models. This work establishes MPZL1 as a viable CAR-T cell target and provides a generalizable framework for exploiting amplified cell surface receptors as broadly applicable therapeutic targets.<\/jats:p>","DOI":"10.1038\/s41467-026-77465-5","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T12:44:25Z","timestamp":1789044265000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cancer-driver-agnostic targeting of amplified surface proteins identifies MPZL1 for selective CAR-T cell therapy"],"prefix":"10.1038","volume":"17","author":[{"given":"Sonia","family":"Jim\u00e9nez-V\u00e1zquez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Berthel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Patsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Mitstorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luise","family":"Butthof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Wendler-Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lio","family":"B\u00f6se","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8450-653X","authenticated-orcid":false,"given":"Hendrik","family":"Wiethoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Breuhahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Longerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias M.","family":"Gaida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schirmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Feucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8892-1546","authenticated-orcid":false,"given":"Meggy","family":"Suarez-Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1917-1446","authenticated-orcid":false,"given":"Patrick","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fee","family":"Klupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Wallwiener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1276-7802","authenticated-orcid":false,"given":"Dirk","family":"Jaeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Halama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9740-2986","authenticated-orcid":false,"given":"Marco","family":"Breinig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2369-5138","authenticated-orcid":false,"given":"Darjus F.","family":"Tschaharganeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"77465_CR1","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.cell.2018.02.060","volume":"173","author":"MH Bailey","year":"2018","unstructured":"Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and mutations. Cell 173, 371\u2013385.e18 (2018).","journal-title":"Cell"},{"key":"77465_CR2","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333\u2013339 (2013).","journal-title":"Nature"},{"key":"77465_CR3","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/j.trecan.2023.07.010","volume":"9","author":"MN Zeissig","year":"2023","unstructured":"Zeissig, M. N., Ashwood, L. M., Kondrashova, O. & Sutherland, K. D. Next batter up! Targeting cancers with KRAS-G12D mutations. Trends Cancer 9, 955\u2013967 (2023).","journal-title":"Trends Cancer"},{"key":"77465_CR4","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med. 384, 2371\u20132381 (2021).","journal-title":"N. Engl. J. Med."},{"key":"77465_CR5","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.1158\/1078-0432.CCR-21-2138","volume":"28","author":"PI Poulikakos","year":"2022","unstructured":"Poulikakos, P. I., Sullivan, R. J. & Yaeger, R. Molecular pathways and mechanisms of BRAF in cancer therapy. Clin. Cancer Res. 28, 4618\u20134628 (2022).","journal-title":"Clin. Cancer Res."},{"key":"77465_CR6","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507\u20132516 (2011).","journal-title":"N. Engl. J. Med."},{"key":"77465_CR7","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/nature08822","volume":"463","author":"R Beroukhim","year":"2010","unstructured":"Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. Nature 463, 899\u2013905 (2010).","journal-title":"Nature"},{"key":"77465_CR8","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","volume":"5","author":"N Harbeck","year":"2019","unstructured":"Harbeck, N. et al. Breast cancer. Nat. Rev. Dis. Prim. 5, 66 (2019).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"77465_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-022-00579-0","volume":"22","author":"SM Swain","year":"2023","unstructured":"Swain, S. M., Shastry, M. & Hamilton, E. Targeting HER2-positive breast cancer: advances and future directions. Nat. Rev. Drug Discov. 22, 101\u2013126 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"77465_CR10","doi-asserted-by":"publisher","first-page":"104355","DOI":"10.1016\/j.critrevonc.2024.104355","volume":"198","author":"M Mart\u00edn","year":"2024","unstructured":"Mart\u00edn, M. et al. Trastuzumab deruxtecan in breast cancer. Crit. Rev. Oncol. Hematol. 198, 104355 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"77465_CR11","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1038\/s41591-023-02379-4","volume":"29","author":"PJ O\u2019Dwyer","year":"2023","unstructured":"O\u2019Dwyer, P. J. et al. The NCI-MATCH trial: lessons for precision oncology. Nat. Med. 29, 1349\u20131357 (2023).","journal-title":"Nat. Med."},{"key":"77465_CR12","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1056\/NEJMra1407390","volume":"371","author":"DP McLornan","year":"2014","unstructured":"McLornan, D. P., List, A. & Mufti, G. J. Applying synthetic lethality for the selective targeting of cancer. N. Engl. J. Med. 371, 1725\u20131735 (2014).","journal-title":"N. Engl. J. Med."},{"key":"77465_CR13","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921 (2005).","journal-title":"Nature"},{"key":"77465_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123\u2013134 (2009).","journal-title":"N. Engl. J. Med."},{"key":"77465_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.trecan.2015.10.002","volume":"1","author":"FL Muller","year":"2015","unstructured":"Muller, F. L., Aquilanti, E. A. & Depinho, R. A. Collateral lethality: a new therapeutic strategy in oncology. Trends Cancer 1, 161\u2013173 (2015).","journal-title":"Trends Cancer"},{"key":"77465_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature11331","volume":"488","author":"FL Muller","year":"2012","unstructured":"Muller, F. L. et al. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488, 337\u2013342 (2012).","journal-title":"Nature"},{"key":"77465_CR17","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature21052","volume":"542","author":"P Dey","year":"2017","unstructured":"Dey, P. et al. Genomic deletion of malic enzyme 2 confers collateral lethality in pancreatic cancer. Nature 542, 119\u2013123 (2017).","journal-title":"Nature"},{"key":"77465_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01357-w","volume":"16","author":"S Krieg","year":"2024","unstructured":"Krieg, S. et al. Mitoferrin2 is a synthetic lethal target for chromosome 8p deleted cancers. Genome Med. 16, 83 (2024).","journal-title":"Genome Med."},{"key":"77465_CR19","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1158\/2159-8290.CD-23-1189","volume":"14","author":"Y Bei","year":"2024","unstructured":"Bei, Y. et al. Passenger gene coamplifications create collateral therapeutic vulnerabilities in cancer. Cancer Discov. 14, 492\u2013507 (2024).","journal-title":"Cancer Discov."},{"key":"77465_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56301-2","volume":"16","author":"V Rendo","year":"2025","unstructured":"Rendo, V. et al. A compendium of amplification-related gain of sensitivity genes in human cancer. Nat. Commun. 16, 1077 (2025).","journal-title":"Nat. Commun."},{"key":"77465_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0121314","volume":"10","author":"D Bausch-Fluck","year":"2015","unstructured":"Bausch-Fluck, D. et al. A mass spectrometric-derived cell surface protein atlas. PLoS ONE 10, 1\u201322 (2015).","journal-title":"PLoS ONE"},{"key":"77465_CR22","unstructured":"The ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium et al. Pan-cancer analysis of whole genomes. Nature 578, 82\u201393 (2020)."},{"key":"77465_CR23","doi-asserted-by":"publisher","first-page":"1260419","DOI":"10.1126\/science.1260419","volume":"347","author":"M Uhl\u00e9n","year":"2015","unstructured":"Uhl\u00e9n, M. et al. Proteomics. Tissue-based map of the human proteome. Science 347, 1260419 (2015).","journal-title":"Science"},{"key":"77465_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/science.aal3321","volume":"356","author":"PJ Thul","year":"2017","unstructured":"Thul, P. J. et al. A subcellular map of the human proteome. Science 356, eaal3321 (2017).","journal-title":"Science"},{"key":"77465_CR25","unstructured":"Firehose: Broad Institute TCGA Genome Data Analysis Center. https:\/\/gdac.broadinstitute.org\/ (2016)."},{"key":"77465_CR26","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.cell.2017.05.046","volume":"169","author":"DA Wheeler","year":"2017","unstructured":"Wheeler, D. A. & Roberts, L. R. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell 169, 1327\u20131341.e23 (2017).","journal-title":"Cell"},{"key":"77465_CR27","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"DC Koboldt","year":"2012","unstructured":"Koboldt, D. C. et al. Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370 (2012).","journal-title":"Nature"},{"key":"77465_CR28","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"EA Collisson","year":"2014","unstructured":"Collisson, E. A. et al. Comprehensive molecular profiling of lung adenocarcinoma: the cancer genome atlas research network. Nature 511, 543\u2013550 (2014).","journal-title":"Nature"},{"key":"77465_CR29","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang, Z., Kang, B., Li, C., Chen, T. & Zhang, Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 47, W556\u2013W560 (2019).","journal-title":"Nucleic Acids Res."},{"key":"77465_CR30","doi-asserted-by":"crossref","unstructured":"Consortium, T. U. UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Res. 51, 523\u2013531 (2023).","DOI":"10.1093\/nar\/gkac1052"},{"key":"77465_CR31","first-page":"1","volume":"224","author":"SA Aleksander","year":"2023","unstructured":"Aleksander, S. A. et al. The gene ontology knowledgebase in 2023. Genetics 224, 1\u201314 (2023).","journal-title":"Genetics"},{"key":"77465_CR32","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.18632\/oncotarget.6226","volume":"7","author":"JL Shi","year":"2016","unstructured":"Shi, J. L. et al. Overexpression of ATP1B1 predicts an adverse prognosis in cytogenetically normal acute myeloid leukemia. Oncotarget 7, 2585\u20132595 (2016).","journal-title":"Oncotarget"},{"key":"77465_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/pore.2022.1610674","volume":"28","author":"W Ma","year":"2022","unstructured":"Ma, W., Zhang, X., Ma, C. & Liu, P. Highly expressed FAM189B predicts poor prognosis in hepatocellular carcinoma. Pathol. Oncol. Res. 28, 1\u201314 (2022).","journal-title":"Pathol. Oncol. Res."},{"key":"77465_CR34","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.jceh.2023.04.004","volume":"13","author":"P Ye","year":"2023","unstructured":"Ye, P. et al. Ephrin-A4 ligand (EFNA4) predicts poor prognosis of hepatocellular carcinoma and promotes tumor proliferation. J. Clin. Exp. Hepatol. 13, 767\u2013773 (2023).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"77465_CR35","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/cr.2013.158","volume":"24","author":"D Jia","year":"2014","unstructured":"Jia, D. et al. Amplification of MPZL1\/PZR promotes tumor cell migration through Src-mediated phosphorylation of cortactin in hepatocellular carcinoma. Cell Res. 24, 204\u2013217 (2014).","journal-title":"Cell Res."},{"key":"77465_CR36","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/s41388-023-02623-8","volume":"42","author":"Y Ding","year":"2023","unstructured":"Ding, Y. et al. EWI2 and its relatives in Tetraspanin-enriched membrane domains regulate malignancy. Oncogene 42, 861\u2013868 (2023).","journal-title":"Oncogene"},{"key":"77465_CR37","doi-asserted-by":"publisher","first-page":"20395","DOI":"10.18632\/aging.203425","volume":"13","author":"JH Xu","year":"2021","unstructured":"Xu, J. H. et al. ADAM15 correlates with prognosis, immune infiltration and apoptosis in hepatocellular carcinoma. Aging 13, 20395\u201320417 (2021).","journal-title":"Aging"},{"key":"77465_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41568-024-00763-x","volume":"25","author":"R Arafeh","year":"2025","unstructured":"Arafeh, R., Shibue, T., Dempster, J. M., Hahn, W. C. & Vazquez, F. The present and future of the cancer dependency map. Nat. Rev. Cancer 25, 59\u201373 (2025).","journal-title":"Nat. Rev. Cancer"},{"key":"77465_CR39","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/abbs\/gmz019","volume":"51","author":"D Tan","year":"2019","unstructured":"Tan, D., Zhang, W., Tao, Y., Galiya, Y. & Wang, M. PZR promotes metastasis of colorectal cancer through increasing FAK and Src phosphorylation. Acta Biochim. Biophys. Sin. 51, 356\u2013364 (2019).","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"77465_CR40","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1093\/carcin\/bgac055","volume":"43","author":"J Feng","year":"2022","unstructured":"Feng, J. et al. MPZL1 upregulation promotes tumor metastasis and correlates with unfavorable prognosis in non-small cell lung cancer. Carcinogenesis 43, 919\u2013929 (2022).","journal-title":"Carcinogenesis"},{"key":"77465_CR41","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.bbrc.2018.10.161","volume":"506","author":"T Yu","year":"2018","unstructured":"Yu, T., Liang, L., Zhao, X. & Yin, Y. Structural and biochemical studies of the extracellular domain of Myelin protein zero-like protein 1. Biochem. Biophys. Res. Commun. 506, 883\u2013890 (2018).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"77465_CR42","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/pin.12407","volume":"66","author":"H Nitta","year":"2016","unstructured":"Nitta, H. et al. The assessment of HER2 status in breast cancer: the past, the present, and the future. Pathol. Int. 66, 313\u2013324 (2016).","journal-title":"Pathol. Int."},{"key":"77465_CR43","unstructured":"User Guide: Dissociated Tumor Cells (DTCs) 1\u201326 (Discovery Life Sciences, 2022)."},{"key":"77465_CR44","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nature22395","volume":"545","author":"M Sadelain","year":"2017","unstructured":"Sadelain, M., Rivi\u00e8re, I. & Riddell, S. Therapeutic T cell engineering. Nature 545, 423\u2013431 (2017).","journal-title":"Nature"},{"key":"77465_CR45","doi-asserted-by":"crossref","unstructured":"Castellanos-Rueda, R. et al. speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing. Nat. Commun. 13, 6555 (2022).","DOI":"10.1038\/s41467-022-34141-8"},{"key":"77465_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biomedicines10102420","volume":"10","author":"D Atar","year":"2022","unstructured":"Atar, D. et al. Adapter CAR T cell therapy for the treatment of B-lineage lymphomas. Biomedicines 10, 1\u201318 (2022).","journal-title":"Biomedicines"},{"key":"77465_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40364-022-00434-9","volume":"10","author":"Y Liu","year":"2022","unstructured":"Liu, Y. et al. Strategies to enhance CAR-T persistence. Biomark. Res. 10, 1\u201318 (2022).","journal-title":"Biomark. Res."},{"key":"77465_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2022.1034257","volume":"10","author":"X Zhu","year":"2022","unstructured":"Zhu, X., Li, Q. & Zhu, X. Mechanisms of CAR T cell exhaustion and current counteraction strategies. Front. Cell Dev. Biol. 10, 1\u201311 (2022).","journal-title":"Front. Cell Dev. Biol."},{"key":"77465_CR49","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh, M. et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature 568, 112\u2013116 (2019).","journal-title":"Nature"},{"key":"77465_CR50","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.1182\/blood-2001-12-0207","volume":"100","author":"M Ito","year":"2002","unstructured":"Ito, M. et al. NOD\/SCID\/\u03b3cnull mouse: an excellent recipient mouse model for engraftment of human cells. Blood 100, 3175\u20133182 (2002).","journal-title":"Blood"},{"key":"77465_CR51","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","volume":"20","author":"F Mart\u00ednez-Jim\u00e9nez","year":"2020","unstructured":"Mart\u00ednez-Jim\u00e9nez, F. et al. A compendium of mutational cancer driver genes. Nat. Rev. Cancer 20, 555\u2013572 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"77465_CR52","first-page":"679","volume":"42","author":"D Chen","year":"2019","unstructured":"Chen, D., Cao, L. & Wang, X. MPZL1 promotes tumor cell proliferation and migration via activation of Src kinase in ovarian cancer. Oncol. Rep. 42, 679\u2013687 (2019).","journal-title":"Oncol. Rep."},{"key":"77465_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0121673","volume":"10","author":"B Forsstr\u00f6m","year":"2015","unstructured":"Forsstr\u00f6m, B. et al. Dissecting antibodies with regards to linear and conformational epitopes. PLoS One 10, 1\u201311 (2015).","journal-title":"PLoS One"},{"key":"77465_CR54","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.3390\/cancers15143536","volume":"15","author":"Y Matsumoto","year":"2023","unstructured":"Matsumoto, Y. & Ju, T. Aberrant glycosylation as immune therapeutic targets for solid tumors. Cancers 15, 3536 (2023).","journal-title":"Cancers"},{"key":"77465_CR55","doi-asserted-by":"publisher","first-page":"100762","DOI":"10.1016\/j.esmoop.2022.100762","volume":"8","author":"Y Kubota","year":"2023","unstructured":"Kubota, Y. et al. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer. ESMO Open 8, 100762\u2013100762 (2023).","journal-title":"ESMO Open"},{"key":"77465_CR56","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41571-024-00874-2","volume":"21","author":"I Nakayama","year":"2024","unstructured":"Nakayama, I. et al. Claudin 18.2 as a novel therapeutic target. Nat. Rev. Clin. Oncol. 21, 354\u2013369 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"77465_CR57","doi-asserted-by":"publisher","first-page":"101233","DOI":"10.1016\/j.xcrm.2023.101233","volume":"4","author":"S Derks","year":"2023","unstructured":"Derks, S. & Laarhoven, V. an H. W. M. SPOTlight on GLOW. Cell Rep. Med. 4, 101233 (2023).","journal-title":"Cell Rep. Med."},{"key":"77465_CR58","doi-asserted-by":"publisher","first-page":"101710","DOI":"10.1016\/j.xcrm.2024.101710","volume":"5","author":"G Xu","year":"2024","unstructured":"Xu, G. et al. CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors. Cell Rep. Med. 5, 101710 (2024).","journal-title":"Cell Rep. Med."},{"key":"77465_CR59","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189\u20131198 (2022).","journal-title":"Nat. Med."},{"key":"77465_CR60","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s10555-015-9552-6","volume":"34","author":"M Yan","year":"2015","unstructured":"Yan, M. et al. HER2 expression status in diverse cancers: review of results from 37,992 patients. Cancer Metastasis Rev. 34, 157\u2013164 (2015).","journal-title":"Cancer Metastasis Rev."},{"key":"77465_CR61","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"77465_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, 1\u201314 (2011).","journal-title":"Genome Biol."},{"key":"77465_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/database\/bar030","volume":"2011","author":"RJ Kinsella","year":"2011","unstructured":"Kinsella, R. J. et al. Ensembl BioMarts: a hub for data retrieval across taxonomic space. Database 2011, 1\u20139 (2011).","journal-title":"Database"},{"key":"77465_CR64","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/bib\/bbs017","volume":"14","author":"H Thorvaldsd\u00f3ttir","year":"2013","unstructured":"Thorvaldsd\u00f3ttir, H., Robinson, J. T. & Mesirov, J. P. Integrative genomics viewer (IGV): high-performance genomics data visualization and exploration. Brief. Bioinform. 14, 178\u2013192 (2013).","journal-title":"Brief. Bioinform."},{"key":"77465_CR65","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"Weinstein, J. N. et al. The cancer genome atlas pan-cancer analysis project. Nat. Genet. 45, 1113\u20131120 (2013).","journal-title":"Nat. Genet."},{"key":"77465_CR66","unstructured":"The GTEx Consortium. The genotype-tissue expression (GTEx) project The GTEx Consortium. Database Natl. Cent. Biomed. Inf. 45, 580\u2013585 (2013)."},{"key":"77465_CR67","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41586-018-0722-x","volume":"565","author":"J Barretina","year":"2019","unstructured":"Barretina, J. et al. Erratum: Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity (Nature (2012) 483 7391 (603-607)). Nature 565, 603\u2013607 (2019).","journal-title":"Nature"},{"key":"77465_CR68","doi-asserted-by":"publisher","first-page":"W171","DOI":"10.1093\/nar\/gkz365","volume":"47","author":"K Labun","year":"2019","unstructured":"Labun, K. et al. CHOPCHOP v3: expanding the CRISPR web toolbox beyond genome editing. Nucleic Acids Res. 47, W171\u2013W174 (2019).","journal-title":"Nucleic Acids Res."},{"key":"77465_CR69","doi-asserted-by":"crossref","unstructured":"Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783\u2013784 (2014)","DOI":"10.1038\/nmeth.3047"},{"key":"77465_CR70","doi-asserted-by":"publisher","unstructured":"Revia, S. et al. Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer. Gut. https:\/\/doi.org\/10.1136\/gutjnl-2021-325405 (2021).","DOI":"10.1136\/gutjnl-2021-325405"},{"key":"77465_CR71","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/hep.22033","volume":"47","author":"C Schlaeger","year":"2008","unstructured":"Schlaeger, C. et al. Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology 47, 511\u2013520 (2008).","journal-title":"Hepatology"},{"key":"77465_CR72","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1002\/hep.25870","volume":"56","author":"O Neumann","year":"2012","unstructured":"Neumann, O. et al. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. Hepatology 56, 1817\u20131827 (2012).","journal-title":"Hepatology"},{"key":"77465_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead, P. et al. QuPath: open source software for digital pathology image analysis. Sci. Rep. 7, 1\u20137 (2017).","journal-title":"Sci. Rep."},{"key":"77465_CR74","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"77465_CR75","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/978-1-4939-9151-8_5","volume":"1956","author":"H Wardemann","year":"2019","unstructured":"Wardemann, H. & Busse, C. E. Expression cloning of antibodies from single human B cells. Methods Mol. Biol. 1956, 105\u2013125 (2019).","journal-title":"Methods Mol. Biol."},{"key":"77465_CR76","doi-asserted-by":"publisher","first-page":"6733","DOI":"10.1073\/pnas.92.15.6733","volume":"92","author":"I Rivi\u00e8re","year":"1995","unstructured":"Rivi\u00e8re, I., Brose, K. & Mulligan, R. C. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl. Acad. Sci. USA 92, 6733\u20136737 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"77465_CR77","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht, J. et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat. Med. 25, 82\u201388 (2019).","journal-title":"Nat. Med."},{"key":"77465_CR78","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/sj.gt.3300947","volume":"6","author":"F Liu","year":"1999","unstructured":"Liu, F., Song, Y. K. & Liu, D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6, 1258\u20131266 (1999).","journal-title":"Gene Ther."},{"key":"77465_CR79","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.ajpath.2013.12.002","volume":"184","author":"X Chen","year":"2014","unstructured":"Chen, X. & Calvisi, D. F. Hydrodynamic transfection for generation of novel mouse models for liver cancer research. Am. J. Pathol. 184, 912\u2013923 (2014).","journal-title":"Am. J. Pathol."},{"key":"77465_CR80","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.ccell.2016.03.005","volume":"29","author":"N Halama","year":"2016","unstructured":"Halama, N. et al. Tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients. Cancer Cell 29, 587\u2013601 (2016).","journal-title":"Cancer Cell"},{"key":"77465_CR81","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-026-02594-8","volume":"11","author":"M Suarez-Carmona","year":"2026","unstructured":"Suarez-Carmona, M. et al. Harnessing lipid-driven immunometabolic pathways in omental metastases to enhance immunotherapy in patients with ovarian cancer. Signal Transduct. Target. Ther. 11, 78 (2026).","journal-title":"Signal Transduct. Target. Ther."},{"key":"77465_CR82","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1158\/1078-0432.CCR-10-2173","volume":"17","author":"N Halama","year":"2011","unstructured":"Halama, N. et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines. Clin. Cancer Res. 17, 678\u2013689 (2011).","journal-title":"Clin. Cancer Res."},{"key":"77465_CR83","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1053\/j.gastro.2012.06.037","volume":"143","author":"M Chmielewski","year":"2012","unstructured":"Chmielewski, M. et al. T cells that target carcinoembryonic antigen eradicate orthotopic pancreatic carcinomas without inducing autoimmune colitis in mice. Gastroenterology 143, 1095\u20131107.e2 (2012).","journal-title":"Gastroenterology"},{"key":"77465_CR84","doi-asserted-by":"publisher","first-page":"e994446","DOI":"10.4161\/2162402X.2014.994446","volume":"4","author":"M Koneru","year":"2015","unstructured":"Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S. & Brentjens, R. J. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology 4, e994446 (2015).","journal-title":"Oncoimmunology"},{"key":"77465_CR85","first-page":"21","volume":"4","author":"I Barde","year":"2010","unstructured":"Barde, I., Salmon, P. & Trono, D. Production and titration of lentiviral vectors. Curr. Protoc. Neurosci. 4, 21 (2010).","journal-title":"Curr. Protoc. Neurosci."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77465-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77465-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77465-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:02:30Z","timestamp":1789048950000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-77465-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":85,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["77465"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-77465-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"9695"}}